Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Ocrelizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche Prsent Ocrevus And Fenebrutinib Data at ECTRIMS 2025
    Roche Prsent Ocrevus And Fenebrutinib Data at ECTRIMS 2025

    24 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/24/3155202/0/en/Roche-presents-new-data-for-OCREVUS-and-fenebrutinib-across-broad-patient-populations-at-ECTRIMS-2025.html

    GLOBENEWSWIRE
    24 Sep 2025
    Share Share
    Genentech Unveils Ocrevus, Fenebrutinib Data At ECTRIMS 2025
    Genentech Unveils Ocrevus, Fenebrutinib Data At ECTRIMS 2025

    24 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250923346934/en/Genentech-Presents-New-Data-for-Ocrevus-and-Fenebrutinib-Across-Broad-Patient-Populations-at-ECTRIMS-2025

    BUSINESSWIRE
    24 Sep 2025
    Share Share
    Polpharma, MS Pharma Ink Licensing Agreements for Biosimilars
    Polpharma, MS Pharma Ink Licensing Agreements for Biosimilars

    02 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250902492755/en/Polpharma-Biologics-and-MS-Pharma-Sign-Licensing-Agreements-for-Proposed-Vedolizumab-PB016-Ocrelizumab-PB018-and-Guselkumab-PB019-Biosimilars

    BUSINESSWIRE
    02 Sep 2025
    Share Share
    Genentech’s Biologic Ocrevus Zunovo Receives Suppl Approval in US
    Genentech’s Biologic Ocrevus Zunovo Receives Suppl Approval in US

    18 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761371

    FDA
    18 Aug 2025
    Share Share
    Roche's high-dose version of Ocrevus flunks phase 3 trial
    Roche's high-dose version of Ocrevus flunks phase 3 trial

    03 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biosimilar-competition-looming-roche-takes-hit-failure-high-dose-ocrevus

    FIERCE PHARMA
    03 Apr 2025
    Share Share
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis
    Genentech Updates Ocrevus High Dose Study in Multiple Sclerosis

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402207576/en/Genentech-Provides-Update-on-Phase-III-Ocrevus-High-Dose-Study-in-People-With-Relapsing-Multiple-Sclerosis

    BUSINESSWIRE
    02 Apr 2025
    Share Share